{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T04:28:29Z","timestamp":1791606509389,"version":"4.3.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s11060-022-04145-x","type":"journal-article","created":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T14:02:33Z","timestamp":1665669753000},"page":"233-240","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Local control of brain metastases with osimertinib alone in patients with EGFR-mutant non-small cell lung cancer"],"prefix":"10.1007","volume":"160","author":[{"given":"Caressa","family":"Hui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jen-Yeu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rie","family":"von Eyben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Cheng","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Lin","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Hung","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jen-Tang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Hayden-Gephart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Wakelee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Neal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavitha","family":"Ramchandran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Millie","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seema","family":"Nagpal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Soltys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathaniel","family":"Myall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erqi","family":"Pollom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,13]]},"reference":[{"key":"4145_CR1","doi-asserted-by":"publisher","first-page":"121","DOI":"10.3346\/jkms.2005.20.1.121","volume":"20","author":"S-Y Kim","year":"2005","unstructured":"Kim S-Y, Kim J-S, Park H-S et al (2005) Screening of brain metastasis with limited Magnetic Resonance Imaging (MRI): clinical implications of using limited brain MRI during initial staging for non-small cell lung cancer patients. J Korean Med Sci 20:121\u2013126. https:\/\/doi.org\/10.3346\/jkms.2005.20.1.121","journal-title":"J Korean Med Sci"},{"key":"4145_CR2","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/s0169-5002(03)00291-5","volume":"42","author":"MMH Hochstenbag","year":"2003","unstructured":"Hochstenbag MMH, Twijnstra A, Hofman P et al (2003) MR-imaging of the brain of neurologic asymptomatic patients with large cell or adenocarcinoma of the lung. Does it influence prognosis and treatment? Lung Cancer 42:189\u2013193. https:\/\/doi.org\/10.1016\/s0169-5002(03)00291-5","journal-title":"Lung Cancer"},{"key":"4145_CR3","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.lungcan.2015.11.011","volume":"90","author":"D Moro-Sibilot","year":"2015","unstructured":"Moro-Sibilot D, Smit E, de Castro CJ et al (2015) Non-small cell lung cancer patients with brain metastases treated with first-line platinum-doublet chemotherapy: analysis from the European FRAME study. Lung Cancer 90:427\u2013432. https:\/\/doi.org\/10.1016\/j.lungcan.2015.11.011","journal-title":"Lung Cancer"},{"key":"4145_CR4","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1200\/JGO.2016.003392","volume":"3","author":"VR Bhatt","year":"2017","unstructured":"Bhatt VR, D\u2019Souza SP, Smith LM et al (2017) Epidermal growth factor receptor mutational status and brain metastases in non\u2013small-cell lung cancer. JGO 3:208\u2013217. https:\/\/doi.org\/10.1200\/JGO.2016.003392","journal-title":"JGO"},{"key":"4145_CR5","doi-asserted-by":"publisher","first-page":"56998","DOI":"10.18632\/oncotarget.10933","volume":"7","author":"G Han","year":"2016","unstructured":"Han G, Bi J, Tan W et al (2016) A retrospective analysis in patients with EGFR-mutant lung adenocarcinoma: is EGFR mutation associated with a higher incidence of brain metastasis? Oncotarget 7:56998\u201357010. https:\/\/doi.org\/10.18632\/oncotarget.10933","journal-title":"Oncotarget"},{"key":"4145_CR6","doi-asserted-by":"publisher","first-page":"2510","DOI":"10.21037\/jtd.2017.07.57","volume":"9","author":"L Li","year":"2017","unstructured":"Li L, Luo S, Lin H et al (2017) Correlation between EGFR mutation status and the incidence of brain metastases in patients with non-small cell lung cancer. J Thorac Dis 9:2510\u20132520. https:\/\/doi.org\/10.21037\/jtd.2017.07.57","journal-title":"J Thorac Dis"},{"key":"4145_CR7","doi-asserted-by":"publisher","first-page":"v534","DOI":"10.1093\/annonc\/mdz255.001","volume":"30","author":"GV Long","year":"2019","unstructured":"Long GV, Atkinson VG, Lo S et al (2019) Long-term outcomes from the randomized phase II study of nivolumab (nivo) or nivo plus ipilimumab (ipi) in patients (pts) with melanoma brain metastases (mets): Anti-PD1 brain collaboration (ABC). Ann Oncol 30:v534","journal-title":"Ann Oncol"},{"key":"4145_CR8","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1200\/JCO.18.00204","volume":"37","author":"HM Kluger","year":"2019","unstructured":"Kluger HM, Chiang V, Mahajan A et al (2019) Long-term survival of patients with melanoma with active brain metastases treated with Pembrolizumab on a phase II trial. J Clin Oncol 37:52\u201360. https:\/\/doi.org\/10.1200\/JCO.18.00204","journal-title":"J Clin Oncol"},{"key":"4145_CR9","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1470-2045(12)70090-6","volume":"13","author":"K Margolin","year":"2012","unstructured":"Margolin K, Ernstoff MS, Hamid O et al (2012) Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol 13:459\u2013465. https:\/\/doi.org\/10.1016\/S1470-2045(12)70090-6","journal-title":"Lancet Oncol"},{"key":"4145_CR10","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1056\/NEJMoa1805453","volume":"379","author":"HA Tawbi","year":"2018","unstructured":"Tawbi HA, Forsyth PA, Algazi A et al (2018) Combined nivolumab and ipilimumab in melanoma metastatic to the brain. N Engl J Med 379:722\u2013730. https:\/\/doi.org\/10.1056\/NEJMoa1805453","journal-title":"N Engl J Med"},{"key":"4145_CR11","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/S1470-2045(17)30429-1","volume":"18","author":"MA Davies","year":"2017","unstructured":"Davies MA, Saiag P, Robert C et al (2017) Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. Lancet Oncol 18:863\u2013873. https:\/\/doi.org\/10.1016\/S1470-2045(17)30429-1","journal-title":"Lancet Oncol"},{"key":"4145_CR12","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1093\/annonc\/mdw641","volume":"28","author":"GA McArthur","year":"2017","unstructured":"McArthur GA, Maio M, Arance A et al (2017) Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study. Ann Oncol 28:634\u2013641. https:\/\/doi.org\/10.1093\/annonc\/mdw641","journal-title":"Ann Oncol"},{"key":"4145_CR13","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/S1470-2045(12)70431-X","volume":"13","author":"GV Long","year":"2012","unstructured":"Long GV, Trefzer U, Davies MA et al (2012) Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol 13:1087\u20131095. https:\/\/doi.org\/10.1016\/S1470-2045(12)70431-X","journal-title":"Lancet Oncol"},{"key":"4145_CR14","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1016\/S0140-6736(12)60398-5","volume":"379","author":"GS Falchook","year":"2012","unstructured":"Falchook GS, Long GV, Kurzrock R et al (2012) RAF inhibitor dabrafenib (GSK2118436) is active in melanoma brain metastases, multiple BRAF genotypes and diverse cancers. Lancet 379:1893\u20131901. https:\/\/doi.org\/10.1016\/S0140-6736(12)60398-5","journal-title":"Lancet"},{"key":"4145_CR15","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"J-C Soria","year":"2018","unstructured":"Soria J-C, Ohe Y, Vansteenkiste J et al (2018) Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med 378:113\u2013125. https:\/\/doi.org\/10.1056\/NEJMoa1713137","journal-title":"N Engl J Med"},{"key":"4145_CR16","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1200\/JCO.2016.70.3223","volume":"35","author":"JC-H Yang","year":"2017","unstructured":"Yang JC-H, Ahn M-J, Kim D-W et al (2017) Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study phase II extension component. J Clin Oncol 35:1288\u20131296. https:\/\/doi.org\/10.1200\/JCO.2016.70.3223","journal-title":"J Clin Oncol"},{"key":"4145_CR17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.78.3118","author":"T Reungwetwattana","year":"2018","unstructured":"Reungwetwattana T, Nakagawa K, Cho BC et al (2018) CNS response to Osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer. J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.2018.78.3118","journal-title":"J Clin Oncol"},{"key":"4145_CR18","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1016\/j.jtho.2021.07.026","volume":"16","author":"H Yamaguchi","year":"2021","unstructured":"Yamaguchi H, Wakuda K, Fukuda M et al (2021) A phase II study of osimertinib for radiotherapy-naive central nervous system metastasis from NSCLC: results for the T790M cohort of the OCEAN study (LOGIK1603\/WJOG9116L). J Thorac Oncol 16:2121\u20132132. https:\/\/doi.org\/10.1016\/j.jtho.2021.07.026","journal-title":"J Thorac Oncol"},{"key":"4145_CR19","doi-asserted-by":"publisher","first-page":"iii20","DOI":"10.1093\/noajnl\/vdab071.082","volume":"3","author":"J-Y Wang","year":"2021","unstructured":"Wang J-Y, Sandhu N, Mendoza M et al (2021) RADI-12. Deep learning for automatic detection and contouring of metastatic brain tumors in stereotactic radiosurgery a retrospective analysis with an FDA-cleared software algorithm. Neurooncol Adv 3:iii20. https:\/\/doi.org\/10.1093\/noajnl\/vdab071.082","journal-title":"Neurooncol Adv"},{"key":"4145_CR20","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"key":"4145_CR21","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s11060-017-2398-8","volume":"132","author":"JM Qian","year":"2017","unstructured":"Qian JM, Mahajan A, Yu JB et al (2017) Comparing available criteria for measuring brain metastasis response to immunotherapy. J Neurooncol 132:479\u2013485. https:\/\/doi.org\/10.1007\/s11060-017-2398-8","journal-title":"J Neurooncol"},{"key":"4145_CR22","doi-asserted-by":"publisher","first-page":"5130","DOI":"10.1158\/1078-0432.CCR-16-0399","volume":"22","author":"P Ballard","year":"2016","unstructured":"Ballard P, Yates JWT, Yang Z et al (2016) Preclinical comparison of Osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity. Clin Cancer Res 22:5130\u20135140. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-0399","journal-title":"Clin Cancer Res"},{"key":"4145_CR23","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1158\/1078-0432.CCR-19-1871","volume":"27","author":"N Colclough","year":"2021","unstructured":"Colclough N, Chen K, Johnstr\u00f6m P et al (2021) Preclinical comparison of the blood-brain barrier permeability of Osimertinib with other EGFR TKIs. Clin Cancer Res 27:189\u2013201. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-1871","journal-title":"Clin Cancer Res"},{"key":"4145_CR24","doi-asserted-by":"publisher","first-page":"907","DOI":"10.3171\/jns.2006.104.6.907","volume":"104","author":"MA Vogelbaum","year":"2006","unstructured":"Vogelbaum MA, Angelov L, Lee S-Y et al (2006) Local control of brain metastases by stereotactic radiosurgery in relation to dose to the tumor margin. J Neurosurg 104:907\u2013912. https:\/\/doi.org\/10.3171\/jns.2006.104.6.907","journal-title":"J Neurosurg"},{"key":"4145_CR25","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1016\/j.ijrobp.2016.03.013","volume":"95","author":"G Minniti","year":"2016","unstructured":"Minniti G, Scaringi C, Paolini S et al (2016) Single-fraction versus multifraction (3 \u00d7 9 Gy) stereotactic radiosurgery for large (>2 cm) brain metastases: a comparative analysis of local control and risk of radiation-induced brain necrosis. Int J Radiat Oncol Biol Phys 95:1142\u20131148. https:\/\/doi.org\/10.1016\/j.ijrobp.2016.03.013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4145_CR26","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1200\/JCO.2016.69.7144","volume":"35","author":"WJ Magnuson","year":"2017","unstructured":"Magnuson WJ, Lester-Coll NH, Wu AJ et al (2017) Management of brain metastases in tyrosine kinase inhibitor-na\u00efve epidermal growth factor receptor-mutant non\u2013small-cell lung cancer: a retrospective multi-institutional analysis. JCO 35:1070\u20131077. https:\/\/doi.org\/10.1200\/JCO.2016.69.7144","journal-title":"JCO"},{"key":"4145_CR27","doi-asserted-by":"publisher","first-page":"603","DOI":"10.3389\/fonc.2018.00603","volume":"8","author":"X-J Du","year":"2018","unstructured":"Du X-J, Pan S-M, Lai S-Z et al (2018) Upfront cranial radiotherapy vs. EGFR tyrosine kinase inhibitors alone for the treatment of brain metastases from non-small-cell lung cancer a meta-analysis of 1465 patients. Front Oncol 8:603. https:\/\/doi.org\/10.3389\/fonc.2018.00603","journal-title":"Front Oncol"},{"key":"4145_CR28","doi-asserted-by":"publisher","first-page":"4406","DOI":"10.1158\/1078-0432.CCR-12-0357","volume":"18","author":"S Heon","year":"2012","unstructured":"Heon S, Yeap BY, Lindeman NI et al (2012) The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations. Clin Cancer Res 18:4406\u20134414. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-0357","journal-title":"Clin Cancer Res"},{"key":"4145_CR29","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s00280-012-1929-4","volume":"70","author":"Y Togashi","year":"2012","unstructured":"Togashi Y, Masago K, Masuda S et al (2012) Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer. Cancer Chemother Pharmacol 70:399\u2013405. https:\/\/doi.org\/10.1007\/s00280-012-1929-4","journal-title":"Cancer Chemother Pharmacol"},{"key":"4145_CR30","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1097\/JTO.0000000000000380","volume":"10","author":"P Hoffknecht","year":"2015","unstructured":"Hoffknecht P, Tufman A, Wehler T et al (2015) Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease. J Thorac Oncol 10:156\u2013163. https:\/\/doi.org\/10.1097\/JTO.0000000000000380","journal-title":"J Thorac Oncol"},{"key":"4145_CR31","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.jtho.2021.08.009","volume":"17","author":"NJ Thomas","year":"2022","unstructured":"Thomas NJ, Myall NJ, Sun F et al (2022) Brain metastases in EGFR- and ALK-positive NSCLC: outcomes of central nervous system-penetrant tyrosine kinase inhibitors alone versus in combination with radiation. J Thorac Oncol 17:116\u2013129. https:\/\/doi.org\/10.1016\/j.jtho.2021.08.009","journal-title":"J Thorac Oncol"},{"key":"4145_CR32","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1634\/theoncologist.2018-0264","volume":"24","author":"L Xie","year":"2019","unstructured":"Xie L, Nagpal S, Wakelee HA et al (2019) Osimertinib for EGFR-mutant lung cancer with brain metastases: results from a single-center retrospective study. Oncologist 24:836\u2013843. https:\/\/doi.org\/10.1634\/theoncologist.2018-0264","journal-title":"Oncologist"},{"key":"4145_CR33","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1227\/01.neu.0000064569.18914.de","volume":"52","author":"T Hasegawa","year":"2003","unstructured":"Hasegawa T, Kondziolka D, Flickinger JC et al (2003) Brain metastases treated with radiosurgery alone: an alternative to whole brain radiotherapy? Neurosurgery 52:1318\u20131326. https:\/\/doi.org\/10.1227\/01.neu.0000064569.18914.de (discussion 1326)","journal-title":"Neurosurgery"},{"key":"4145_CR34","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1080\/02688690902755613","volume":"23","author":"R Molenaar","year":"2009","unstructured":"Molenaar R, Wiggenraad R, Verbeek-de Kanter A et al (2009) Relationship between volume, dose and local control in stereotactic radiosurgery of brain metastasis. Br J Neurosurg 23:170\u2013178. https:\/\/doi.org\/10.1080\/02688690902755613","journal-title":"Br J Neurosurg"},{"key":"4145_CR35","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1097\/RLI.0b013e3181c02ed5","volume":"45","author":"H-C Bauknecht","year":"2010","unstructured":"Bauknecht H-C, Romano VC, Rogalla P et al (2010) Intra- and interobserver variability of linear and volumetric measurements of brain metastases using contrast-enhanced magnetic resonance imaging. Invest Radiol 45:49\u201356. https:\/\/doi.org\/10.1097\/RLI.0b013e3181c02ed5","journal-title":"Invest Radiol"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-022-04145-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-022-04145-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-022-04145-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T09:09:02Z","timestamp":1667207342000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-022-04145-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["4145"],"URL":"https:\/\/doi.org\/10.1007\/s11060-022-04145-x","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"24 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"For authors Yu-Cheng Chang, Po-Lin Chiang, Chih-Hung Liang, Jen-Tang Lu, a US patent is granted for Vysioneer software, and these authors also have Vysioneer Inc. stocks. For author Scott Soltys: Zap Surgical, Inc.\u2014Speaker Honoraria; Novocure, Inc.\u2014Research Funding; Accuray, Inc.\u2014Consultant. For author Millie Das: Consulting: Jazz Pharmaceutics, Beigene, Astra Zeneca, Sanofi\/Genzyme, Eurofins, Janssen, Genentech (uncompensated). Research: Merck, Genentech, CellSight, Novartis, Abbvie, United Therapeutics, Varian, Verily, Celgene. For author Melanie Hayden-Gephart: U54CA261717. All other authors have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study did not require ethics approval.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}